Talk:Disease-modifying antirheumatic drug

Medicine Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Other biologics[edit]

Here it lists only adalimumab and infliximab, but rheumatoid arthritis lists

tumor necrosis factor alpha (TNFα) blockers - etanercept (Enbrel), infliximab (Remicade), adalimumab (Humira)
Interleukin 1 (IL-1) blockers - anakinra (Kineret)
monoclonal antibodies against B cells - rituximab (Rituxan)[28]
T cell costimulation blocker - abatacept (Orencia)
Interleukin 6 (IL-6) blockers - tocilizumab (an anti-IL-6 receptor antibody) (RoActemra, Actemra)

Rod57 (talk) 15:52, 25 November 2009 (UTC)[reply]

Drug Mechanisms[edit]

The mechanisms should be referenced. The gold salts mechanism is proposed and hypothetical not confirmed. —Preceding unsigned comment added by 129.170.107.63 (talk) 02:44, 2 June 2010 (UTC)[reply]

Approved or investigational[edit]

Could we add to the members table the FDA approval date, and maybe in a separate table list investigational drugs in phase 3 clinical trials ? Rod57 (talk) 12:26, 10 November 2010 (UTC)[reply]